AU667048B2 - Bioresorbable material and an article of manufacture made of such material for medical use - Google Patents
Bioresorbable material and an article of manufacture made of such material for medical use Download PDFInfo
- Publication number
- AU667048B2 AU667048B2 AU22823/92A AU2282392A AU667048B2 AU 667048 B2 AU667048 B2 AU 667048B2 AU 22823/92 A AU22823/92 A AU 22823/92A AU 2282392 A AU2282392 A AU 2282392A AU 667048 B2 AU667048 B2 AU 667048B2
- Authority
- AU
- Australia
- Prior art keywords
- plasticizer
- weight
- lactide
- article
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000463 material Substances 0.000 title claims description 114
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000004014 plasticizer Substances 0.000 claims description 66
- 229920000642 polymer Polymers 0.000 claims description 58
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 45
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 30
- 229920001577 copolymer Polymers 0.000 claims description 26
- 239000004626 polylactic acid Substances 0.000 claims description 24
- 239000004310 lactic acid Substances 0.000 claims description 22
- 235000014655 lactic acid Nutrition 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 229920006125 amorphous polymer Polymers 0.000 claims description 16
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 15
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 14
- -1 1-lactide Chemical compound 0.000 claims description 11
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 10
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 229920001610 polycaprolactone Polymers 0.000 claims description 8
- 239000004632 polycaprolactone Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 4
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000622 polydioxanone Substances 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000003903 lactic acid esters Chemical class 0.000 claims description 2
- 230000008961 swelling Effects 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 15
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 10
- 230000003239 periodontal effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- BUPOYFBEEGMBJU-UHFFFAOYSA-N 5-tert-butyl-4,5-dihydro-1,3-oxazol-2-amine Chemical compound CC(C)(C)C1CN=C(N)O1 BUPOYFBEEGMBJU-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 5
- 230000017423 tissue regeneration Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 229940073584 methylene chloride Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 101150005771 ATR1 gene Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101100230100 Caenorhabditis elegans tbc-6 gene Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 101100480530 Danio rerio tal1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101100480538 Mus musculus Tal1 gene Proteins 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 241000277269 Oncorhynchus masou Species 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 101100312945 Pasteurella multocida (strain Pm70) talA gene Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- CCFQLQIYEHITNK-UHFFFAOYSA-N Polycarpol Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C)C)CC(O)C4(C)C3=CCC21 CCFQLQIYEHITNK-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000012859 tissue stain Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Description
667 0 4 8 P00/001oooo Regulation 3.2
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name of Applicant: GUIDOR AB Actual Inventor(s): Dan LUNDGREN, Jan GOTTLOW and Torbjorn MATHISEN.
a r w sc r r
D
r r c r r
I
Address for service in Australia: CARTER SMITH BEADLE Qantas House 2 Railway Parade Camberwell Victoria 3124 Australia Attorney Code CD Invention Title: BIORESORBABLE MATERIAL MANUFACTURE MADE OF MEDICAL USE AND AN ARTICLE OF SUCH MATERIAL FOR The following statement is a full description of this invention, including the best method of performing it known to us: Our Ref: #11032 MW:WB 09-27gui -1- The present invention relates to a bioresorbable material and an article of manufacture made of such material for medical use to be implanted into a living organism, e.g. for selective influences on the healing process by guiding tissue growth, e.g. in healing after periodontal surgery (guided periodontal tissue regeneration) and in connection with regeneration of other hard and soft intra- and extra-oral tissues, the element preferably being in the form of an element, layer(s), foil, sheet or film, but the element may also be formed as a filament or tube, During the last decades biodegradable materials have been increasingly widely used in the medical field.
.Initially collagen was introduced which, however, causes 2 problems due to the fact that it has an irregular degradation time and may cause inflammatory and in some cases allergic reactions. Since the beginning of 1970 new materials with improved characteristics, in terms of biodegradation time and biocompatibility, have been S* developed, primarily polyglycolic acid (PGA) and 25 polylactic acid (PLA). PGA and PLA have been successful commercially and are used today for medical applications, e.g. as sutures and orthopedic pins, applications where above all material strength is required.
The tissue regeneration applications mentioned in the introduction require another set of characteristics of the elements being used (aside from biodegradability and biocompatibility), primarily malleability at the time of surgery, and dimensional stability of the material during the healing phase after being implanted in vivo.
Malleabklity as used herein is a led-like plasticity, i.e. the material does not immediately or 2 over a short period regain the shape that it had before it was reshaped, which means that the material has no or very little memory. Malleability according to this definition is important at the time of surgery so that the material can be located along the tissue to be covered and the shape of the material can be adapted to the shape of the region to be covered, often in a threedimensional fashion. This characteristic facilitates the surgical procedure. Moreover, absence of a memory of the element assures that the adjacent tissue is exposed to a minimum of pressure.
Dimensional stability is important so that an appropriate design or shape imparted to the material can be maintained over a certain period of time which often 15 can be definea the period which is critical for the healing process. Dimensional stability reduces the 0: tendency of the material to swell thereby eliminating a possible second source of pressure to the tissues adjacent to the implanted element.
WO 90/7308 describes several embodiments of an element for guiding tissue growth in regeneration of supporting tissues of teeth and dental implants, in healing after periapical operations, and in connection with filling of bone cavities caused by cysts and malformations, and diastases caused by bone fractures. In said application polymers are said to be suitable materials for the biodegradable element, and among others polylactide (PLA) is mentioned.
PLA can be pliable if woven or knitted but is hardly malleable. It is moreover very difficult if at all 'possible to make structures other than those inherent in the weaving or knitting techniques. By using other known manufacturing technique, such as compression molding, injection molding, or calendering among others, it is in 3 fact possible to make small structures in PLA that are stable over a certain period, but such structures would not be malleable and would fracture easily due to the physical state of the PLA polymer itself. Polytrimethylene carbonate is a bioresorbable material which is soft but elastic rather than malleable, i.e. it will spring back when folded. Due to a low glass transition temperature this material has poor dimensional stability, and moreover, the bioresorption thereof extends over a long time, probably no less than two years, which could be a disadvantage, e.g. in the periodontal application, and has specific negative consequences, e.g. in the periodontal application where there is a connection between the bioresorbable element and the oral cavity 15 with the consequent increased risk for infection.
w:'c WO 88/04557 describes implants of different kinds which have desired mechanical and physiological properties and in a living organism have an unexpected favourable influence on the cell growth and the tissue regeneration. These implants comprise at least one basic polymer component and at least one hydrophobic polymer component which is at least as hydrophobic as lactide.
The material of these implants can comprise bioresorable polymers with a plasticizer added.
Plasticizers from the citrate ester family and triacelin have been in use to impart greater flexibility and suturability to nerve guidance tubes as mentioned in E" 0.226 061. These nerve guidance tubes are preferably made from poly-d,l-lactide but can also consist of polymers containing other a-hydroxy acids.
S US 4 961 707 describes a membrane for guided periodontal tissue regeneration made from a bioresorable material; among others poly lactic acid is mentioned, in which an additive may be incorporated. Among others, the 4 additive could be a plasticizer from the citrate ester family.
US 5 032 445 describes method and articles for treating periodontal desease and bone defects. When an article is used it should be made from a biocompatible, porous material selected from, among others, polycarboxylates and polyesters.
S. Yolles reports the use of tri-n-butyl citrate as a plasticizer for polylactic acid microspheres for sustained release of drugs (Yolles, S. Journal of 'Parenteral Drug Association, vol. 32(4), 188-191, 1978) and (Yolles, Leafe, Ward, Boettner, F.
Bulletin of the Parenteral DRug Association, vol. 30(6), 306-312, 1976). The only comment given regarding tri-nbutyl citrate is that it had a small effect cn the release rate of the drug used.
E.W. Henry reports the use of 2 to 10 triethyl citrate to plasticize poly-d,l-lactide which was used "among other materials to study the regneration of a damaged nerve by the use of tubes that protect the nerve ends during healing (Henry, Chiu, T-H; Nyilas, E.; Brushart, Dikkes, Siedman, Swelling of the material was recognized as a problem.
There is little or no information in the patent and scientific literature regarding the effect in terms of new properties obtained when a plasticizer is incorporated in the group of polymers commonly known as bioresorbable polymers, such as polymers, copolymers or blends thereof made from the group of monomers including glycolic acid, lactic acid, caprolactone, trimethylene carbonate, paradioxanone, and 1,5-dioxepan-2-one. These materials all have the characteristic that they are degraded by hydrolysis in the human body to harmless hydroxy acids or alcohols which can be metabolized or excreted. The hydrolysis occurs through out the bulk of a device made of such bioresorbable materials as mentioned above and more acidic and alcoholic end groups are formed from the hydrolysis, which create a more hydrophilic environment in the device. More water penetrates into the bulk of the device than degradation products are leaving the same, which can be observed as a weight increase of the device by gravimetric analysis. This absorbed water creates a force from the interior that acts on the device, causing it to swell, if the device has a low modulus of elasticity, characterised as soft, or to disintegrate if the modulus of elasticity is high, characterised as hard. The disintegration will then occur first when the mechanical strength of the device has been 15 lowered, due to degradation, to such an extent that the internal force is higher than the tensile strength of the material of the device. Polymers made of glycolic acid, lactic acid, caprolactone and paradioxanone are all Spolymers with high modulus of elasticity, while polymers of trimethylene carbonate and 1,5-dioxepan-2-one are examples of polymers with low modulus of elasticity. The modulus can be changed by copolymerization or by blending the different polymers.
9* To reduce the modulus of elasticity a plasticizer 25 can be added to the polymer. It is, however, necessary that the plasticizer is compatible with the polymer so that the plasticizer is evenly distributed in the polymer. The plasticizer acts in a way like a lubricant for the polymer chains and increases the mobility in the system. This may also increase the ability of water to penetrate into the bulk of a device made from such a plasticized material. Tha strength of the material in such an element will be lower than that of the unplasticized material and, therefore, the swelling will be more pronouned and in some instances so severe that the material will have no practical use.
The property of swelling for the above mentioned polymers is a natural consequence of hydrolysis and can not be hindered if one wants to have a resorbable material. When a plasticizer is added the swelling increases due to reduced mechanical strength of the plasticized material. Accordingly, only through careful selection of plasticizer and polymer, copolymer or blends thereof acceptable properties of a material to be used for a specific purpose can be achieved. The reason of incorporating a plasticizer, as found in some of the references cited above, has been to reduce the modulus of elasticity or to make an otherwise brittle material more flexible so that it can be bent or deformed without fracture. Polymers like poly-d,l-lactide or copolymers of lactide and glycolide are usually very brittle in their pure state. Plasticizers like citrate esters have little or no effect on the rate of resorption of the polymers 20 mentioned above. However, the plasticizer triacetin has such an effect which may be explained by its rapid hydrolysis to glycerol and acetic acid. The liberated S* acetid acid may act as a catalyst for the hydrolysis of the polymer.
25 The term internal plasticization is often used for systems when two monomers whose homopolymers have different glass transition temperatures (Tg) are copolymerized. Normally one polymer has a low Tg and the other a high Tg like poly-trimethylene carbonate (PTMC), Tg being approximately -18 0 C, and poly-d,l-lactide (d,l- PLA), Tg being approximately 57 0 C. The copolymer made from these monomers will have a Tg ranging from -18 to 57 0 C depending on the ratio of the two monomers. Internal plasticization of poly-d,l-lactide can thus be achieved 7 achieved by incorporating trimethylene carbonate into the chain. For example, a monomer ratio of 70/30 between d,llactide and trimethylene carbonate (TMC) yields a copolymer with Tg approximately 25 0 C. The same effect of internal plasticization can be achieved by the use of caprolactone instead of TMC as the comonomer. Such polymers are described by S.J. Hanson et al (Hanson, Jamshidi, K; Eberhart, R.C. Trans.Am. Soc. Intern.
Organs, vol. XXXIV, 789-793, 1988) for evaluation of their potential use as vacular grafts and in GB 8918343 as a material than can be used for periodontal regeneration. This patent application demonstrates both the lowering of Tg and the reduction in modulus of elasticity as a consequence of internal plasticization.
1,5-dioxepan-2-one which yields upon polymerization a homopolymer with Tg of -390C, according to Mathisen et al (Mathisen, Masus, K; Albertsson, A.C. Macromolecules, 22, 3842-3846, 1989), can furthermore be copolymerized with lactides or glycolides to yield a material with the same effect of internal plasticization as that mentioned S" above.
~However, only the term reduction of the modulus of elasticity is often not enough to express the property often desired in an element for surgical application.
25 Certain cross linked rubbers like silicones or polyurethanes, characterized by low hardness, 30-80 Shore A, feel very soft and have a low modulus of elasticity but have a high memory. All polymeric materials have the u nique time dependent property called visco elasticity, which means that upon release of a non permanent deforming load the material will eventually regain its shape. If the material was purely elastic it would immediately retain its shape. For visco elastic materials it will take a certain time to regain the shape depending may not fully regain their shape and are said to be plastically deformed, deformation occuring without rupture.
The cross linked rubbers mentioned above, silicones and polyurethanes, cannot be plastically deformied by small forces due to their cross links which remember what the device looked like when the cross links were formed..
These materials have a memory and always return to their original shape after the load has been released unless the material ruptures during deformation. The internal plasticized copolymers mentioned above also have a high degree of memory even though they may have a low modules of elasticity. Plasticizing these copolymers further with low molecular weight molecules compatible with the copolymner will reduce the memory that, decrease the viscosity in the system consisting of the plasticizer and the copolymer. This means that the time to regain the original shape increases after release of a small load.
Such low molecular weight molecules, referred to as S 20 plasticizers, may be, but are not limited to, ethyl butyl, and hexyl esters of acetylated or non-acetylated citric acid, ethyl terminated oligomers, of lactic acid, wherein the number of lactic acid units ranges from 2 to and lactic acid esters of glycerol. These plasticizers act in the same way in order to plasticize homopolyners such as the amorphous poly-d,l-lactide or the amorphous copolymers of glyc~olide and lactide. By incorporating the plasticizer in a correct ratio which depends' on the properties of the polymer, copolymer or blends thereof, a material with very little momory or a led-like plasticity can be achieved. This makes the material malleable, which means that it is easy to def~orm and shape.
From what has been said above about bioresorbable polymers and plasticization of such polymers, it is clear that increased malleability in such materials only can be achieved at the expense of increased swelling and, consequently, impaired dimensional stability. During recent years, however, there has arisen an increased demand of bioresorbable materials and elements that strike an advantageous balance between malleability and dimensional stability.
The purpose of the present invention is to provide a bioresorbable and biocompatible element which combines malleability and dimensional stability so as to be advantageous in tissue regeneration and guiding applications.
Accordingly, the invention provides bioresorbable material with plasticizer adaptable for medical use comprising: bioresorbable polymer comprising at least one amorphous polymer or copolymer selected from the group consisting of poly-d, 1-lactide, and copolymers of d, 1-lactide and caprolactone, 1-lactide, or trimethylone carbonate, said amorphous polymer comprising at least 50% by weight of said material; at least one crystalline polymer selected from the group consisting of poly-l-lactide, polycaprolactone and polydioxanone; and a plasticizer selected from the group consisting of S' 25 triethyl, tributyl and trihexyl esters of acetylated citric acid, and ethyl-terminated oligomers of lactic acid having no less than 2 and no more than 10 units of lactic acid, the amount of said plasticizer ranging from substantially 5 to substantially 25% by weight of said composition.
30 The invention further provides an article of manufacture adaptable for medical use made from a bioresorbable material with plasticizer comprising: bioresorbable polymer comprising at least one amorphous polymer or copolymer selected from the group consisting of poly-d, 1-lactide, and copolymers of d, 1-lactide and caprolactone, 1-lactide, or trimethylene carbonate, said amorphous polymer comprising at least 50% by weight of said material; ISPC Slnwuy 19 at least one crystalline polymer selected from the group consisting of poly-l-lactide, polycaprolactone and polydioxanone; and a plasticizer selected from the group consisting of triethyl, tributyl and trihexyl esters of acetylated citric acid, and ethyl-terminated oligomers of lactic acid having no less than 2 and no more than 10 units of lactic acid, the amount of said plasticizer ranging from substantially 5 to substantially 25% by weight of said composition.
In another embodiment, the invention provides a bioresorbable material with plasticizer adaptable for medical use comprising: bioresorbable polymer comprising at least one amorphous polymer or copolymer selected from the group consisting of poly-d, 1-lactide, and copolymers of d, 1-lactide and caprolactone, 1-lactide, or trimethylene carbonate, said amorphous polymer or copolymer comprising at least 50% by weight of said material; and a plasticizer based on ethyl-terminated lactic acid oligomers having no less than 2 and no more than 10 units of lactic acid, in an amount, ranging from substantially 5 to substantially 25% by weight of said composition, to impart to said material a recovery time to regain shape after deformation of more than 5 seconds.
25 The inventors have found that the components should be Se combined in such a way as to make the material substantially malleable and substantially permanent in the shape imparted 'thereto without significant spring back. In other words, the material should lack or have marginal memory function so as to 30 be more easily handled when it is to be implanted into the organism, the material at the same time being more compatible with surrounding tissue; a material which springs back can irritate or cut through surrounding tissue and may be difficult to handle practically at the surgery.
35 To impart to an element the property of having plastic malleability substantially without memory the proportion plasticizer should preferably be of the order ranging from 5 to by weight. The optimum varies depending on MAW:PIUM320ULSPC 12 Jaiuuy 1996 the composition of the polymer. The optimum falls between 9 and 17% by weight if the polymer is based on PLA and the plasticiser is based on citrate esters; it is around 20% by weight with the same polymer but with ethyl terminated lactic acid oligomers as the plasticiser agent. It must be understood that the bending module of a rectangular bar is dependent on the third power of the thickness of the bar. That means that a thick bar will feel more stiff than a thin bar and therefore need r' -re force to be deformed. Thicker elements therefore may need more plasticiser added than thinner elements in order for the elements to have the same malleability. The figures of plasticisers above correspond to an element having a thickness in the range of 30 pm to 1000pm and preferably in the range from 50 to 150 pm.
The major component in the material should be a bioresorbable polymer comprising at least one amorphous polymer or copolymer selected from the group consisting of poly-d, 1lactide, and copolymers of d, 1-lactide and caprolactone, 1lactide, or trimethylene carbonate, said amorphous polymer comprising at least 50 by weight of said material; and any blends thereof that is compatible with the plasticiser in order to achieve a homogenous blend and to impart to the element an 0 acceptable plastic malleability. The material may further comprise at least one crystalline polymer selected from the 25 group consisting of poly-l-lactide, polycaprolactone and polydioxanone.
l a The material compositions include compositions that are suitable as vehicles for the delivery of biochemical substances, e.g. antibiotics such as tetra and minicycline, 30 antiseptics such as clorhexidine, and growth stimulating substances such as Transforming Growth Factor beta, Insulinlike Growth Factor 1, Insulin-like Growth Factor 2, Platelet Derived Growth Factor and Bonemorphogenic Growth Protein.
By the polymer mixture having been plasticized in order to impart to the material the intended malleability, the material will, however, absorb water and such absorption causes swelling of the material to a degree which varies depending on the type of plasticizer used and the concentration thereof. In order to envision the relationship between the swelling of such plasticized polymers and the properties of the plasticizer and polymer itself several mixtures where made in order to quantity the swelling of such blends. The following is a short general description of how the polymer plasticizer blends were made.
Approximately 25 g of polymer and plasticizer were dissolved in 250 ml of methylene chloride in order to obtain a homogeneous solution. The solution was placed in a cupboard overnight in order to allow most of the solvent to evaporate in order to furm a polymer film of g: the mixture. The polymer film was transferred to a vacuum oven, and a vacuum of 1 mbar or less was applied. After 24 hours the temperature in the oven was raised to and the film was left under this condition for 9 days.
This vacuum dried film was then compression molded into a thin sheet with a thickness of 0.2 mm. From this sheet circular test samples 10 mm in diameter were punched out and used for the determination of swelling.
The swelling was determined by exactly measuring toro the thickness of each test sample both prior to and after .ageing in a saline phosphate buffer solution, pH 7.4. The samples were incubated at 37 0 C during the test. Measuring of thickness was performed by the use of a dial gauge.
12 TABLE 1 Change n thickness, Composition 10 days 20 days di-PLA ily. 0.8 1 2 590 wt-% dYl-PLA Lv. 0.6/10 wt-% TEC 8 wt-% dji-PLA iLv. 1.5/10 wt-% TEC 5 wt-%4 di-PLA Lv. 0.5/15 wt.% TEC 63 105 wt-% dI-PLA i.v. 0.8/15 wt-% TEC 10 31 wt-% dOlPLA ikv. 1.5/15 wt-% TEO 8 13 wt-%X di-PLA i.v. 0.8/10 wt-% TBC 2 8 wt-% dl.PLA Wv. 1.5/10 wt-% TBC 3 9 wt-% dl.PLA i.v. 1.5115 wt-% TBC 6 16 90 wt-% di-PLA lv. 0,8/10 wt-% ATBO 1 3; d,i-PLA Lv. 1,5/10 wt-% ATBO 4 wt-% dI-PLA Wv. 0,8115 wt-% ATBO 2 wt-% di-PLA Wv. 1.5/15 wt-% ATBC 3 wt-% di-PLA Lv. 0.8/15 wt-% ETL 168 21 wt-% dj-PLA 1.5/15 wt-% ETL 6 8 di-PLA Lv. 0,5/20 ETL 49 wt-% di-PLA iW. 0,8/20 wt-% ETL 15 w't-A d.PLA l.v, 1.5/20 ETL 141 1 2 .6dI.PLA =Poy-d,l.Iactide :TEC Triethyl ctrate TBO Tributyl citrate 00 ATBO -Acetyltri butyl citrato 20 E Ethyl terminated oligorner of lactic acid, mainly trimer.
Lv. Inherent viscosity 0 9 Tal 1 bv9hwssm fth oye Vo 44 lsiie9obntosofatocmoetsse n thi bltyt wl atr1 nd2 asoficbto '3 oftebfe ouin9s*a eseteseln beaiu eed o h 'eua wih ftebs swl stetyeo lsiie.I a geeal*ese htwtr oul lsiieslk TEC tend to swell the polymeric material more than a water-insoluble plasticizer such as ATBC does. Increase in the molecular weight of poly-d,l-lactide increases he swelling when the plasticizer is ATBC while the opposite is true for TEC as the plasticizer. At present there is no explanation for this behaviour.
TABLE 2 Change of thickness, Composition wt-% d,l-PLA Lv. 0.8/5 wt.% POU5 wt-. ATBO 4 wt-% dj-PLA 1,v. 0,8/20 wt-% PCLJ5 wt-% ATBC 37 81 d 1 1-PLA I,v. 0.8/9 wt.% I-PLA/10 wt-% ATBO 4 6 4 wt-% d -I-PLA I.v. 1.5/9 -PLA10 wt-9/ ATOC 6 6 76 wt%11 di-PLA Ixv. 0.8/9 wt.% l-PLA/15 wt.% AT8C 4 6 76 wt-% d,I.PLA i.v. 1.5/9 wt.% I-PLAJ15 wt-% ATBC 3 wilOV dI-PLA ly. 0,8/60 wt-% PTMC 0 1 wt dI-PLA Lv. 0.8/40 wi-% PTMC 1 3 wt-% d,!r'LA 1.v. 0.8/20 wt.% PTMC 3 4 5 76 wt di-PLA l~v 0 M/ PTMC/1 5 ATBC 3 1 0 72 wt-% di-PLA 1.v, 0.8/18 PMC/1 vt-% ATBO 6 p.76 wt-% djkPLA LV, 0.8/9 wt-% PTMC/15 wt%0/ ETL 4 S *66 wt-% dWbPLA iLv. 0.8/19 wl-%Y PTMC/15 wt-% ETL 61 13 e ~dI.PLA Poly-di-lactide ,POL Poly- caprol acton e I -PLA -Poly H-actide PTMC Poly-trimethylene carbonate ATBC Aceryltri butyl citrate *.ETL Ethyl terminated oligjomer of lactic acid, mainly trimer.
so Table 2 shows examples of swelling of materials 0 composed of a three component system, that is two polymers and one plasticizer. Table 2 only shows blends of polymers but amorphous copcdiymers which have been 0mentioned earlier when discussing internal plasticization could as well have been used as the base polymer rather than poly-d,l-lactide. As can be seen the swelling is drastically reduced by the introduction of a small amount of a crystalline polymer like poly-l-lactide and polycaprolacton. Also the more hydrophob-ic pol.y trimethylene carbonate has the ability to reduce the swelling but not to such an extent.
As can be seen from Table 1 and 2 the swelling can be up to 100 and in some cases even up to 200 measures as thickness increase, especially for copolymers of glycolide and lactide plasticized with water soluble plasticizers such as TEC or triacetin. In the human body or in vitro the swelling may be magnitudes higher and no easy correlation has been found so that dimensional changes can be accurately predicted for an element implanted in vivo. In vivo studes indicate possible swelling of 300 and more for certain combinations of plasticizer and copolymer like for instance low molecular weight poly-d,l-lactide plasticized with 14 wt-% TEC.
Often the swelling has a negative biological influence by forcing an increased pressure on the surrounding tissue, which e.g. in the periodontal application can cause rupture of a repositioned flap. The swelling will, .furthermore, impair the dimensional stability of the material and thereby jeopardizing those structures, if any, that an element made of the material may have been provided with, such as pores, perforations, depressions, ribs, grooves or spacers. In order to minimize the aswelling of such an element while maintaining the e malleability thereof the inventors have found techniques to augment the stability of the material thus minimizing 25 the tendency of the material to swell.
To reduce drastically the tendency of swelling of the plasticized polymer, the element made of the material ,of the invention is perforated. This allows tissue ingrowth into the perforation apertures, resulting in firm integration of the element at the surgical site. Invivo studies clearly indicate that the pressure on the layers of the element from such integrated tissue is higher than the pressure caused by the inflow of water into the element, swelliig of the element thus being counteracted. The perforation apertures must be sufficiently large for the tissue integration to take place before the time of the exponential-like increase of the dimensions of the element. The time of occurrence of this event varies depending on the material composition but typically takes place at around 20-30 days in relatively stable compositions. Furthermore, the perforation apertures must be positioned close to each other on the element.
To be effective the individual apertures as well as the total aperture area ("transparency") of the element must have a minimum size. The individual perforations must be at least 10 um in diameter. This is necessary for cells to grow through the perforation accompanied by a sufficient volume of collagen tissue to achieve the intended timely integration between tissues from both sides of the element. The "transparency" of a layer on an element should probably be at least 6 The intended :.integration will be accomplished faster if the 20 "transparency" and the aperture size is larger. Thus an element or a layer of the material of the invention will swell less with a larger area covered by apertures. The S.a upper limit of the "transparency" and aperture size (transverse dimension) is limited by mechanical 25 properties of the material and the intended function of the element.
It is favourable in order to augment the dimen- *0 sional stability to include a portion of a crystalline polymer into the composition, between 5 and 40 by weight depending on the level of stability requested.
Examples of compositions (by weight) are: 1) 76 poly-d,l-lactide, 10 poly-l-lactide and 14 acetyltri-n-butyl citrate (ATBC).
2) 75 poly-d,l-lactide, 10 poly-caprolactone and 15 ATBC.
3) 80 poly-d,l-lactide and 20 ethyl terminated oligomer of lactic acid.
Although the perforation has been found to be particularly advantageous in connection with elements consisting of the compositions of the invention, the inventors are aware of the fact that such perforations may be advantageous in augmenting the stability of other polymers that are used in biodegradable and biocompatible elements not demonstrating the specific malleability of the material proposed according to the invention, and also for other applications than those referred to herein.
15 In order to explain the invention in more detail embodiments thereof will be described below, reference *e being made to the accompanying drawings in which *e S! t FIG. 1 is a plan view of an element of the material of the invention in one embodiment thereof, 20 FIG 2 is a diagrammatic view of an apparatus for measuring the plastic malleability; FIG. 3 is a cross-sectional view of the element in FIG. 1, 2" FIG. 4 is a view similar to that of FIG. 3, showing 25 another embodiment of the element having spacers on one 5 side of the double-wall structure, FIGS. 5 and 6 are histological pictures disclosing S: the importance of the perforation in reducing swelling of the material, and FIG. 7 is a comparative diagram showing the swelling of an element of the material of the invention with and without perforation, respectively.
The elements disclosed in the drawings are both of the type described in WO 90/07308 with reference to FIGS.
21 and 22 therein and comprise a sandwich structure made of a rectangular blank 10 having two substantially equal portions 11A and 11B shown fragmentarily only in FIG. 1.
This blank is a foil having a thickness e.g. of about 100 um and is e.g. of the size 10 x 20 mm. The blank is made of the polymer material of the invention and more particularly of a polylactide with plasticizer and was prepared as follows: A mixture (example 1 mentioned above) comprising 37,5 g poly-d,1-lactide g poly-l-lactide g acetyltri-n-butyl citrate (ATBC) (plasticizer) were aissolved in 500 ml methylenechloride in order to get a homogeneous solution. The solution was 15 placed in a cupboard overnight in order to allow most of the solvent to evaporate in order to form a polymer film of the mixture. The polymer film was transferred to a vacuum oven, and a vacuum of 1 mbar or less was applied.
After one day the temperature in the oven was raised to 60 0 C and the film was left under this condition for 9 days.
The material thus produced has plastic malleability substantially without memory. The marginal memory function or very little memory of a material can be 0* 25 defined by using the time for an element of such material to regain shape after deformation by a small load, hereinafter denoted recovery time. To standardize such a measuremenet of recovery time a simple apparatus as shown in FIG 2 can be used. A strip 10 mm wide, 55 mm in length and 0.2 0.005 mm in thickness is used for the test. The specimens is clamped between two metal jaws at A so that the sample touches the periphery of a cylinder B. As seen in FIG 2 the length of the free hanging test sample from the point it touches the cylinder and out shall be 35 mm.
18 When the specimen has been clamped in the correct fashion it is gently folded around the cylinder B and further down to a resting plate C where the specimen is hold against this plate for 10 seconds before it is released.
The specimen will then start to regain its original shape as a linear non-bent specimen. A polyuretane or silicone rubber will immediately regain its shape in a shap-back fashin with no permanent bend. This means that recovery time is so small that it is not measurable. For plasticized polymers as mentioned above the time for recovery will vary depending on the polymer and the plasticizer used. A definition of a material having plastic malleability substantially without memory will in this test have recovery time of more than 5 seconds for the bend to be reduced from initial 90 degrees to *degrees. It is understood that the test is performed in o; an environment with 30 0 C. The specimen must be conditioned in this atmosphere 24 hous before being .tested.
The blank 10 of FIG 1 wau produced by compression molding, but other manufacturing methods can be applied such as callendering, casting, molding, or other techniques, Portion 11B forms at one side thereof protrusions 12 which have the shape of truncated cones with a base diameter of about 0.4 mm and a height of about 0.2 mm. The protrusions of one row thereof adjacent portion 11A have a center distance of about 0.6 mm, and the center distance of the remaining rows being about 1.2 mm and the center distance between the rows being about 1.0 mm.
When a bioresorbable polymer is mixed with a plasticizer there is a problem with swelling due to increased absorption of water in the material as a consequence of the plasticizer having been added. The swelling may be of the order of 300 By this swelling the blank made of the material may disrupt and the element may cause pressure on adjacent tissues with possible negative consequences, as mentioned above. The swelling problem can be limited by combining components that impart to the material some hydrophobicity so as to limit the water absorption, and crystallinity so as to improve the strength of the material. However, the swelling can also be reduced by perforation of the element, and such perforation has been found in vivo to reduce swelling substantially. This method of reducing ,swelling is applied to the blank 10 manufactured as described above by treating the blank in order to perforate the portion 11A. The perforation apertures 13 15 are rectangular in shape 0.2 x 0.4 mm and the center :distance between the apertures in each row is about mm and between the rows about 0.35 mm. The apertures cover about 40 of the surface area of portion 11A.
2 As shown in FIG 3 the blank of FIG 1 has been 20 folded to form a double-wall structure or laminate wherein the adjacent surfaces of portions 11A and 11B are spaced by the protrusions 12 at a distance of 0.2 mm to create a free space between the surfaces. The protrusions 12 forming spacers between portions 11A and 11B are glued 25 to portion 11A. The glue used is a mixture of 17 by :weight of poly-d,l-lactide and 3 by weight acetyltri-nbutyl citrate in ethyl acetate forming the rest of the mixture.
A suture 14 for tying the sandwich type element of FIG 2 to a tooth with the smooth outside surface of portion 11B facing the tooth is located in a space defined between portions 11A and 11B by a rib or bar 16 extending over the full width of portion 11B and protruding at both sides thereof, and the adjacent protrusions 12, to be used In the modified embodiment disclosed in FIG 4 the portion 11B forms at the outside surface thereof protrusions 17 distributed over the surface in the same configuration as protrusions 12 and having a height of about 0.1 mm. These protrusions are provided to form spacers between the outside surface of portion 11B and the surface of the tooth. Moreover, there are provided small circular apertures 18 having a typical aiameter of m and arranged in a hexagonal pattern wherein the center distance of the apertures is about 0.2 mm. These apertures cover an area of about 15 of the surface area.
15 Elements of the two types described above have been implanted in periodontal defects around teeth in the oral cavity of monkeys (Macaca Fascicularis). In the e experimental model an incision was made and a mucoperiosteal flap was raised to expose the bone, which was resected to surgically create a recession-type defect.
The element was cut to shape to fit the profile of the defect. Using the attached suture 14, the element then was tied to the tooth in the cemento-enamel region, so that the element completely covered the defect. The flap S 25 was repositioned and secured with sutures to cover the element and defect area.
The monkeys were given antibiotics at the time of surgery. Plaque control was maintained by topical application on teeth and surrounding gingiva, once a week, of a chlorhexidine solution. The monkeys were sacrificed 4 and 6 weeks after surgery. Following sacrifice, the jaws were removed and specimens containing the experimental teeth and their periodontal tissues were dissected and placed in a solution of 10 buffered formalin. The specimens were decalcified in EDTA, dehydrated and embedded in paraffin. Bucco-lingual sections of each specimen were prepared with the microtome. The sections were stained with hematoxylin eosin or Mallory's connective tissue stain. From each root sections were used for microscopic analysis.
In all elements of the FIG. 3 embodiment, i.e.
without apertures in portion 11B facing the root surface, a severe swelling of the element could be noticed, typically from 140 um to 600 pm or, expressed in percentage of the initial thickness of the element before implantation, the swelling was of the order of 300 or more. In portion 11A having the rectangular apertures 13 the order of swelling was 60 For elements of the FIG 4 S 15 embodiment having apertures 16 in portion 11B the magnitude of the swelling was about 60 for both portions 11A and 11B.
0 0, FIG. 5 illustrates the swelling of an element of the type shown in FIG. 3 such swelling occurring in S 20 portion 11B while portion 11A is uneffectd by swelling, and the substantially reduced swelling of such material O: when perforated, marked by solid arrows. FIG. 6 shows an t. element of the type shown in FIG. 4 made of the same material as the element in FIG. 5 and having perforation 25 in both layers. This figure demonstrates substantially reduced or substantially eliminated swelling of portion 1183.
The diagram in FIG. 7 finally illustrates the results of measurements made on elements according to FIGS. 3 and 4 of the material of the invention columns A referring to portion 11A and columns B referring to portion 11B. The columns represent the measured width of said portions. The vertical axis indicates the measures 4 22 width in mm, and the horizontal axis indicates the type of perforation used according to the table 3 below: TABLE 3 Type Membrane Perforation Transparency 00 gO 0 0 0 0 Og 0 0@ 09 0 0* 0 0 0 *0 00 p ~0 00 0 00 0 0 00 0 0 go 0* 0 9090 09 00 00 00 00 0000 0 0 0000 0000 0 0 0000 00 *0 00 0
IV
II
IvI
IV
vi vii Portion Portion
II
Portion to Portion Ii Portion ri Portion Portion 11iA 11B3 11A 11B 11A 11B 11A 11B 11A 11B 11A 11B 11A 11B Circular aperture diameter 200im Unperforated Circular aperture diameter 300 4m ;Unperforated Circular aperture diameter 300/ m Unperforated Rectangular aperture 200 x 400/4m Unperforated Rectangular aperture 200 x 400 um Unperforated Circular aperture diameter 300/m Circular aperture diamntor 60/mn Rectangular aperture 200 x 400/m Circular aperture diameter 300/.m 31 51 31 41 41 T L. ±11, ii mi 11 ii-ninriiiir iii-n-itirAliiiii liL.:liLir 11 'rill iill The material of the elements was that specified in example 1 above.
These findings clearly indicate a close relationship between a perforated element and the dimensional stability thereof when made of a plasticized polylactide.
The factor responsible for the increase of the dimensional stability clearly depends on the shape of the perforation apertures and on the size and number of the perforation apertures.The optimum may vary for an element of one, two or more layers or for elements of different configurations as earlier referred to.
The claims form part of the disclosure of this specification.
04 o *t f f *t ff *t f *tt f ft ft f ft ft f ft ftf.f
Claims (19)
1. Bioresorbable material with plasticizer adaptable for medical use comprising: bioresorbable polymer comprising at least one amorphous polymer or copolymer selected from the group consisting of poly-d, l-lactide, and copolymers oi d, 1-lactide and caprolactone, 1-lactide, or trimethylene carbonate, said amorphous polymer comprising at least 50% by weight of said material; at least one crystalline polymer selected from the group consisting of poly-l-lactide, polycaprolactone and poly- dioxanone; and a plastic*izer selected from the group consisting of triethyl, tributyl and trihexyl esters of acetylated citric acid, and ethyl-terminated oligomers of lactic acid having no les than 2 and no more than 10 units of lactic acid, the amount of said plasticizer ranging from substantially 5 to substantially 25% by weight of said composition.
2. An article of manufacture adaptable for medical use made from a bioresorbable material with plasticizer comprising: bioresorbable polymer comprising at least one amorphous polymer or copolymer selected from the group consisting of 1-lactide, and copolymers of d, 1-lactide and 25 caprolactone, 1-lactide, or trimethylene carbonate, said amorphous polymer comprising at least 50% by weight of said material; at least one crystalline polymer selected from the group consisting of poly-l-lactide, polycaprolactone and poly- S 30 dioxanone; and a plasticizer selected from the group consisting of triethyl, tributyl and trihexyl esters of acetylated citric acid, and ethyl-terminated oligomers of lactic acid r. having no less than 2 and no more than 10 units of lactic acid, the amount of said plasticizer ranging from substantially 5 to substantially 25% by weight of said composition. t R:IIO32GUIZSC IS Jnury 1996
3. The bioresorbable material of claim 1, wherein said crystalline polymer ranges from about 5 to 40% by weight of said material.
4. The bioresorbable material of claim 1, wherein the plasticizer is at least one citrate ester, and that the proportion of plasticizer ranges from substantially 9 to substantially 17% by weight of said material.
The bioresorbable material of claim 1, wherein the plasticizer is at least one ethyl-terminated lactic acid oligomer, and said plasticizer comprises about 20% by weight of said material.
6. The bioresorbable material of claim 1, wherein said material comprises about 76% by weight poly-d, 1-lactide, by weight poly-l-lactide as polymers, and 14% by weight acetyltri-n-butyl citrate as said plasticizer.
7. The bioresorbable material of claim 5, wherein said material comprises about 75% by weight poly-d, 1-lactid6 and by weight polycaprolactone as polymers, and 15% by weight acetyltri-n-butyl citrate as said plasticizer.
8. The article of claim 2, wherein said crystalline polymer ranges from about 5 to 40% by weight of said material.
9. The article of claim 2, wherein said amorphous polymer is based on polylactic acid and said plasticizer is at least one citrate ester, and that the proportion of plasticizer ranges 25 from substantially 9 to substantially 17% by weight of the said bioresorbable material.
10. The article of claim 2, wherein said amorphous polymer is *based on polylactic acid, the plasticizer is at least one ethyl-terminated lactic acid oligomer and said plasticizer 30 amounts to about 20% by weight of said bioresorbable material.
11. The article of claim 2, wherein said bioresorbable material comprises about 76% by weight poly-d, 1-lactide and 10% by weight poly-l-lactide as polymers, and 14% by weight acetyltri-n-butyl citrate as said plasticizer. 35
12. The article of claim 2, wherein said bioresorbable material comprises about 75% by weight poly-d, 1-lactide and by weight polycaprolactone as polymers, and 15% by weight Sacetyltri-nl-utyl citrate as said plasticizer. T 2W.RRl32UISPC I i Jnu*y 1996 ^J
13. The article of claim 2, wherein said bioresorbable material comprises about 80% by weight poly-d,1-lactide, and by weight of at least one ethyl-terminated lactic acid oligomer as said plasticizer.
14. The article of claim 2, wherein said article comprises a medical device comprising apertures formed by perforating.
The article of claim 14, wherein said apertures have a minimum transverse dimension of
16. The article of claim 14, wherein the total area of said apertures is at least 6%.
17. The article of claim 14, wherein said apertures are spaced at a center to center distance ranging from about 700pm to 150pm.
18. Bioresorbable material in accordance with any one of claims 1, 3 to 7 substantially as hereinbefore described with reference to the examples.
19. An article in accordance with any one of claims 2, 8 tc 17 substantially as hereinbefore described with reference to the examples. DATED: 12 January 1996 CARTER SMITH BEADLE Patent Attorneys for the Applicant: 6 *o 9 0 6 0 0 *0 04-SEP-199 113: 48 STROHl GULLI<KSH 7D 46 4 ;JiSY lYY UID JI ABSTRACT The invention relates to a bioresrbable material and an article of manufacture of such material for medical ucc comprising hompolymers, copolymers, or a blend thereof selected from the group of monomers including glycolic acid, lactic acid, caprolactone, trimeLylene carbonate, paradioxanone and 1,5 dioxepan-2- one, a plasticizer selected from the group including ethyl, butyl and hexyl esters of acetylated or non- acetylated citric acid, ethyl terminated oligomers of lactic acid, having no less than 2 and no more than units, and lactic acid esters of glycerol, the material comprises at least 50 of amorphous polymer or polymers to impart Lo the material plastic malleability 15 substantially without memory. eseec
1992-03-04 S/sal V 1211-005
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU22823/92A AU667048B2 (en) | 1992-09-07 | 1992-09-07 | Bioresorbable material and an article of manufacture made of such material for medical use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU22823/92A AU667048B2 (en) | 1992-09-07 | 1992-09-07 | Bioresorbable material and an article of manufacture made of such material for medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2282392A AU2282392A (en) | 1994-03-31 |
| AU667048B2 true AU667048B2 (en) | 1996-03-07 |
Family
ID=3711976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU22823/92A Ceased AU667048B2 (en) | 1992-09-07 | 1992-09-07 | Bioresorbable material and an article of manufacture made of such material for medical use |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU667048B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988004557A1 (en) * | 1986-12-17 | 1988-06-30 | Allied Corporation | Implantable devices having hydrophobic component |
| US5061281A (en) * | 1985-12-17 | 1991-10-29 | Allied-Signal Inc. | Bioresorbable polymers and implantation devices thereof |
| AU8660191A (en) * | 1990-09-06 | 1992-03-30 | Biopak Technology, Ltd. | Packaging thermoplastics from lactic acid |
-
1992
- 1992-09-07 AU AU22823/92A patent/AU667048B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061281A (en) * | 1985-12-17 | 1991-10-29 | Allied-Signal Inc. | Bioresorbable polymers and implantation devices thereof |
| WO1988004557A1 (en) * | 1986-12-17 | 1988-06-30 | Allied Corporation | Implantable devices having hydrophobic component |
| AU8660191A (en) * | 1990-09-06 | 1992-03-30 | Biopak Technology, Ltd. | Packaging thermoplastics from lactic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2282392A (en) | 1994-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5525646A (en) | Bioresorbable material and an article of manufacture made of such material for medical use | |
| Hutmacher et al. | A review of material properties of biodegradable and bioresorbable polymers and devices for GTR and GBR applications. | |
| Bourke et al. | Polymers derived from the amino acid L-tyrosine: polycarbonates, polyarylates and copolymers with poly (ethylene glycol) | |
| US5468253A (en) | Elastomeric medical device | |
| Cameron et al. | Synthetic bioresorbable polymers | |
| US6113624A (en) | Absorbable elastomeric polymer | |
| US5061281A (en) | Bioresorbable polymers and implantation devices thereof | |
| Vert et al. | Bioresorbability and biocompatibility of aliphatic polyesters | |
| CA2363262C (en) | Bioabsorbable, biocompatible polymers for tissue engineering | |
| EP1401510B1 (en) | Biodegradable polymer systems | |
| US5358475A (en) | High molecular weight bioresorbable polymers and implantable devices thereof | |
| AU667048B2 (en) | Bioresorbable material and an article of manufacture made of such material for medical use | |
| WO1988004557A1 (en) | Implantable devices having hydrophobic component | |
| JP2001192337A (en) | Anti-adhesion material | |
| Leenstra et al. | Biodegradation of non-porous films after submucoperiosteal implantation on the palate of Beagle dogs | |
| Chu | Biodegradable polymers: an overview | |
| CN113368309A (en) | Barrier film | |
| EP1878451A1 (en) | Bioabsorbable, biocompatible polymers for tissue engineering | |
| CA2494203A1 (en) | Resorbable thin membranes | |
| EP2569024B1 (en) | Biocompatible material and device | |
| Vert | Understanding of the Bioresorption of PLA/GA Polymers with Respect | |
| Lee | The role of free radicals in biodegradable polymeric biomaterials | |
| Vert | Lactic and glycolic acid-based bioresorbable polymeric materials in ACL reconstruction | |
| Davos | EARLY DURAL REACTION TO POLYLACTIDE IN CRANIAL DEFECTS OF RABBITS | |
| Andrade et al. | Gregonis, DE, Chen, CM, and Andrade, JD (1976). The chemistry of some selected methacrylate hydrogels, in Hydrogels for Medical |